In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ikonisys gets US nod to market automated prenatal diagnostic:

This article was originally published in Clinica

Executive Summary

The US FDA has given Ikonisys clearance to market its automated scanning microscope-based test for prenatal genetic diagnosis. The Ikoniscope fastFISH amnio test system is an in vitro diagnostic for aiding in the detection of the most common chromosomal aneuploidies for chromosomes 21 (Down's syndrome), 18 (Edward syndrome), 13 (Patau syndrome) and for numerical aberrations for sex chromosomes X and Y. The test can provide a result within 24-36 hours. Commenting on the US approval, Ikonisys chairman and CEO Petros Tsipouras said: "It will give us the opportunity to market our first product - to the largest market in the world."

You may also be interested in...



Teladoc Health Acquires Livongo In $18.5Bn Deal, Creating Virtual Care Giant

The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.   

Regeneron Pipeline Progresses On Several Fronts Despite COVID-19 Focus

Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.

Market Intel: Why Telehealth, Digital Therapies Will Provide Mental Health Support Beyond COVID-19 Crisis

In this second part of a two-part series focusing on mental health tech, Medtech Insight highlights behavioral digital health companies that have attracted investors’ attention. Part one focused on transcranial magnetic stimulation.

Topics

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel